Richmond, Feb. 14, 2024 (GLOBE NEWSWIRE) -- According to a research report "Cancer Immunotherapy Market”, by Therapy Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors {CTLA-4, PD-1/PD-L1}, Immunomodulators, Conjugated Antibodies, Non-Specific Immunotherapy, Targeted Vaccine Therapy {Tumor Cell Vaccine, Antigen Vaccine, Peptide-Based Vaccine, DNA-Based Vaccine, Dendritic Cell Vaccine and Others}, Cancer type (Lung Cancer, Bladder Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head And Neck Cancer, Lymphoma, Sarcoma And Others), End Users (Hospitals, Cancer Research Centers, Clinics, and Others) and Region - Global Forecast to 2030.
Global Cancer Immunotherapy Market Report Scope:
Report | Details |
Market size value in 2023 | USD 122.3 Billion |
Market size value in 2030 | USD 217.9 Billion |
CAGR (2023-2030) | 8.6% |
Forecast Period | 2023–2030 |
Historic Data | 2019 |
Forecast Units | Value (USD Million/USD Billion) |
Segments Covered | Therapy Type, Cancer Type, End User and Region |
Geographies Covered | North America, Europe, Asia Pacific, and RoW |
| |
| |
Sample of Companies Covered |
|
| |
|
Download the Sample - https://www.marketdigits.com/request/sample/4063
TOC Covers in Depth & Breath on Cancer Immunotherapy Market
170 - Market Data Tables
65 - List of Figures
225 – Pages
The report includes Vendor Assessment (Company Profiles, Market Positioning, Strategies, Recent Developments, Capabilities & Product Offerings / Mapping), Technology Assessment (Developments & Economic Impact), Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional FootPrint by MarketDigits.
Market Overview
The cancer immunotherapy market has experienced significant growth and transformation recently, developing the approach to cancer treatment. Immunotherapy, a novel method, utilizes the body's immune system to identify and eliminate cancer cells. This market is gaining value due to its ability to provide personalized and individualized treatment options, reducing harm to healthy tissues. Companies within the market are actively working on developing innovative immunotherapeutic agents, including immune checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines. Important drugs like pembrolizumab, nivolumab, and ipilimumab have been approved, marking a significant advancement in cancer care with improved survival rates and long-term benefits for patients.
The cancer immunotherapy market is characterized by competitiveness, with continuing research driving progress. The understanding of the immune system's involvement in cancer advances, and businesses are making substantial investments to develop therapies that are not only stronger but also involve fewer side effects. Collaborations between pharmaceutical companies, academic institutions, and research organizations are prevalent, aiming to expedite the development and accessibility of cancer immunotherapies. Despite challenges such as high treatment costs and the need for effective biomarkers to predict patient response, the overall outlook for the cancer immunotherapy market remains optimistic. Continuous efforts are being made to enhance existing therapies and explore new possibilities to harness the power of the immune system in cancer. This dynamic environment signifies a promising future for cancer patients and underscores the assurance of investors to advance the field of cancer immunotherapy.
Major Vendors in the Global Cancer Immunotherapy Market:
- Amgen Inc.
- Janssen Global Services, LLC
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb
- CRISPR Therapeutics
- F. Hoffmann-La Roche Ltd
- Gritstone Bio
- GSK plc
- Immunocore Ltd.
- Lilly. All rights reserved.
- Merck & Co., Inc.
- Novartis AG
- Sanofi
- Takeda Pharmaceutical Company Limited
Request for Discount @ https://www.marketdigits.com/request/discount/4063
Growing Awareness about The Benefits Of Immunotherapy
One of the primary drivers for the global cancer immunotherapy market is the growing awareness about the benefits of immunotherapy. The reason behind the increasing understanding among healthcare professionals and patients about the advantages of immunotherapy in the cancer immunotherapy market is due to a change in the way of cancer treatments. Immunotherapy uses the body's immune system to recognize and destroy cancer cells, offering a promising alternative to traditional treatments like chemotherapy and radiation therapy. Healthcare professionals, including oncologists and researchers, are recognizing the potential of immunotherapy to provide better outcomes for cancer patients. Patients are also becoming more informed and taking an active role in their healthcare, looking for treatments that not only target the cancer but also minimize side effects and improve their overall quality of life. The demand for immunotherapeutic interventions is increasing, driving market growth and encouraging further research and investment in the development of new and more effective immunotherapies for various types of cancer.
Market Dynamics
Drivers:
- Growing awareness among healthcare professionals and patients
- Regulatory approvals of immunotherapeutic drugs
- Advancements in understanding the immune system's role in cancer
Opportunities:
- Rising demand for targeted and personalized cancer therapies
- Developing combination therapies to enhance the efficacy of cancer immunotherapies
- Increasing investment in research and development for innovative immunotherapeutic agents
- Expanding collaborations and partnerships among pharmaceutical companies
Increasing Investment In Research And Development For Innovative Immunotherapeutic
The growing opportunity in the cancer immunotherapy market is due to increased investment in research and development (R&D) for innovative immunotherapeutics. This means a prominent trend towards advancing treatment methods, driving the development of advanced immunotherapeutic agents like immune checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines. The considerable financial support allocated to R&D activities acts as a catalyst for exploring new approaches and improving existing immunotherapies. Pharmaceutical companies, research institutions, and academic organizations are dedicating significant resources to explain the potential of the immune system in various cancers. The focus on innovative R&D efforts has led to the quicker identification of biomarkers, optimization of treatment protocols, and the emergence of more effective and personalized immunotherapeutic interventions. The cancer immunotherapy market is entering a transformative phase with a rise in the area of novel immunotherapies, providing a unique opportunity to address medical needs and significantly enhance patient outcomes.
Avail 25% Discount on Direct Purchase - Click the below link to proceed: https://www.marketdigits.com/checkout/4063?lic=s
North America dominates the market for Cancer Immunotherapy.
In North America, the cancer immunotherapy market is growing strongly, driven by established pharmaceutical and biotechnology companies, advanced healthcare infrastructure, and significant investments in research and development. The region benefits from a high prevalence of cancer cases and a supportive regulatory environment, leading to the quick approval and use of immunotherapeutic agents. Collaboration between industry players and academic institutions further speeds up the development and availability of innovative cancer immunotherapies
Asia Pacific region, the market for cancer immunotherapy is expanding due to increasing cancer cases, rising healthcare spending, and a growing focus on personalized medicine. The Asia Pacific market has a diverse patient population and a growing middle class, boosting the demand for advanced and effective cancer treatments. Government initiatives, such as funding for cancer research and development, are also driving the growth of the cancer immunotherapy market in the Asia Pacific, making it a crucial region for market expansion and investment opportunities.
In Europe, the cancer immunotherapy market is growing progressively, supported by well-established healthcare infrastructure, a high prevalence of cancer cases, and ongoing research and development efforts. Government initiatives and collaborations between industry and research institutions contribute to the expansion of the market in the region.
The Monoclonal Antibodies Segment is anticipated to hold the Largest Market Share during the Forecast Period
In the global cancer immunotherapy market, the therapy segment comprises various categories such as monoclonal antibodies, immune checkpoint inhibitors, immunomodulators, conjugated antibodies, non-specific immunotherapy, targeted vaccine therapy, and others. The monoclonal antibodies (mAbs) segment within the cancer immunotherapy market stands out as a key contributor, transforming the field of cancer treatment. Monoclonal antibodies are engineered molecules designed in laboratories to target specific proteins in cancer cells, aiding the immune system in recognizing and eliminating these malignant cells. Ongoing research in the monoclonal antibodies segment focuses on creating new antibodies that target different cancer biomarkers. The success of monoclonal antibodies in enhancing patient outcomes, minimizing adverse effects, and improving overall quality of life has led to their widespread adoption. Collaborations between pharmaceutical companies and research institutions are increasing the development of next-generation monoclonal antibodies, promising continued advancements in cancer immunotherapy.
Segmentations Analysis of Cancer Immunotherapy Market: -
- By Therapy Type
- Monoclonal Antibodies
- Immune Checkpoint Inhibitors
- Ctla-4
- Pd-1/Pd-L1
- Immunomodulators
- Conjugated Antibodies
- Non-Specific Immunotherapy
- Targeted Vaccine Therapy
- Tumor Cell Vaccine
- Antigen Vaccine
- Peptide-Based Vaccine
- Dna-Based Vaccine
- Dendritic Cell Vaccine
- Others
- Others
- By Cancer Type
- Lung Cancer
- Bladder Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head And Neck Cancer
- Lymphoma
- Sarcoma
- Others
- By End Users
- Hospitals
- Cancer Research Centers
- Clinics
- Others
- By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Inquire Before Buying: https://www.marketdigits.com/request/enquiry-before-buying/4063
Browse Similar Reports:
Lung Cancer Screening Software Market 2030 By Type, Distribution Channel, End-user and Region - Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional Footprints by MarketDigits
Next Generation Cancer Diagnostics Market 2030 By Type, Distribution Channel, End-user and Region - Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional Footprints by MarketDigits
Cancer Supportive Care Drugs Market 2030 By Type, Distribution Channel, End-user and Region - Partner & Customer Ecosystem (Product Services, Proposition & Key Features) Competitive Index & Regional Footprints by MarketDigits
About MarketDigits:
MarketDigits is one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We at MarketDigits believe that a market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.
We offer services that are most relevant and beneficial to the users, which help businesses to sustain themselves in this competitive market. Our detailed and in-depth analysis of the markets catering to strategic, tactical, and operational data analysis & reporting needs of various industries utilize advanced technology so that our clients get better insights into the markets and identify lucrative opportunities and areas of incremental revenues.
Contact Us:
MarketDigits
1248 CarMia Way Richmond,
VA 23235,
United States.
USA: +1 847 450 0808
Email: sales@marketdigits.com
Web: https://www.marketdigits.com
Follow Us on: | Twitter | LinkedIn |